Treosulfan NDA Resubmitted to FDA

TORONTO and CHICAGO, July 25, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for treosulfan...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news